Perigon Wealth Management LLC Grows Stock Holdings in Cencora, Inc. (NYSE:COR)

Perigon Wealth Management LLC increased its stake in Cencora, Inc. (NYSE:COR) by 15.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,427 shares of the company’s stock after buying an additional 325 shares during the period. Perigon Wealth Management LLC’s holdings in Cencora were worth $585,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in COR. Concord Wealth Partners purchased a new stake in shares of Cencora in the third quarter worth $30,000. Householder Group Estate & Retirement Specialist LLC increased its stake in Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after purchasing an additional 69 shares in the last quarter. Ashton Thomas Securities LLC purchased a new position in Cencora in the third quarter worth about $41,000. Modus Advisors LLC bought a new position in shares of Cencora in the fourth quarter worth approximately $54,000. Finally, Carolina Wealth Advisors LLC grew its holdings in shares of Cencora by 366.7% during the third quarter. Carolina Wealth Advisors LLC now owns 266 shares of the company’s stock valued at $60,000 after buying an additional 209 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the completion of the sale, the chairman now owns 306,752 shares in the company, valued at approximately $74,283,064.32. This trade represents a 6.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 73,187 shares of company stock valued at $17,790,912 over the last quarter. 10.80% of the stock is currently owned by company insiders.

Cencora Trading Down 1.7 %

Shares of COR stock opened at $254.11 on Friday. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The company has a market cap of $49.11 billion, a price-to-earnings ratio of 33.84, a PEG ratio of 1.61 and a beta of 0.49. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $261.25. The firm has a fifty day moving average price of $238.74 and a 200-day moving average price of $235.83.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were given a $0.55 dividend. This is a boost from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.87%. Cencora’s dividend payout ratio is presently 29.29%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on COR. Evercore ISI boosted their price objective on shares of Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Wells Fargo & Company upped their price target on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a report on Wednesday. JPMorgan Chase & Co. lifted their price objective on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Mizuho began coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price on the stock. Finally, Leerink Partners reduced their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research note on Monday, October 7th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $278.40.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.